drugset / Trial / NCT01225640

PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay

NCT01225640

Phase 2 Completed 59 enrolled Sequella, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

PNU-100480 is being developed for the treatment of both drug resistant and sensitive tuberculosis. This is an efficacy and safety study to characterize the effect of PNU-100480 when given for 14 days to treatment-naive patients with drug-sensitive pulmonary tuberculosis.

Timeline

Start
2011-08
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ethambutol Small molecule 275 mg
Comparator Isoniazid Small molecule 75 mg
Comparator Pyrazinamide Small molecule 400 mg
Comparator Rifampin Small molecule 150 mg
Subject Sutezolid Small molecule 600 mg
Subject Sutezolid Small molecule 1200 mg

Indications